|
CLINICAL STUDY:
Prescriptive Patient Extracorporeal Circuit and Oxygenator Sizing Reduces Hemodilution and Allogeneic Blood Product Transfusion during Adult Cardiac Surgery. JECT. 2013; 45:167-172. Bronson S, et al. (PDF)
|
|
ABSTRACT:
Beneficial Effects of Modern Perfusion Concepts in Aortic Valve and Aortic Root Surgery. Perfusion 2009;24: 37-44, Kutschka, et al.
In this 170-patient study, the use of the ROCSafe™ Hybrid Perfusion System was found to reduce side effects of standard extracorporeal circulation.
|
|
ABSTRACT:
Investigation of Blood Compatibility of PMEA-Coated Extracorporeal Circuits. Journal of Bioactive and Compatible Polymers, Vol 17, Sept 2002. Kocakulak M, et al.
In a study comparing PMEA-coated and uncoated oxygenators, the authors found greater retention of clotting factors and platelets and less post-op hemorrhaging when using PMEA-coated oxygenators.
|
|
ABSTRACT:
Emerging Technologies in Biocompatible Surface Modifying Additives: Quest for Physiologic CPB. Cardiovascular and Hematological Agents. 2004; Vol. 2:No 4. Gunaydin S, et al.
The authors compare surface coatings, including Xcoating, in 155 CPB cases for chemical composition, biomaterial evaluation and clinical efficacy.
|
|
ABSTRACT:
Biocompatibility of Poly (2-methoxyethylacrylate) Coating for Cardiopulmonary Bypass. Annals Thoracic Cardiovascular Surgery, 2003, Volume 9, No 1. Noguchi, et al.
The authors compare the biocompatibility of PMEA-coated and heparin-coated circuits by measuring several inflammatory markers. Results indicate PMEA-coated circuits are as biocompatible as heparin coated circuits.
|
|
ABSTRACT:
Xcoating: A New Biopassive Polymer Coating. Canadian Perfusion Canadienne, Volume 11, No 2, June 2001. Schiel, et al.
This paper explains the mechanism and benefits of Xcoating.
|
